Actoxumab

• CAT Number: I042430
• CAS Number: 1245634-25-6
• Molecular Weight: 145.9 (kDa)
• Purity: ≥95%

Actoxumab (Cat No.: I042430) is a human monoclonal antibody designed to neutralize toxin A produced by Clostridioides difficile (C. difficile), a major cause of antibiotic-associated diarrhea and colitis. It was developed as part of a combination therapy with bezlotoxumab, which targets toxin B, aiming to reduce recurrence of C. difficile infections. Although actoxumab showed promise in neutralizing toxin A, clinical trials did not demonstrate significant added benefit over bezlotoxumab alone, leading to its discontinuation. It remains a reference in targeted immunotherapy research.

Reference

[1]. Yang Z, et al. Mechanisms of protection against Clostridium difficile infection by the monoclonal antitoxin antibodies actoxumab and bezlotoxumab. Infect Immun. 2015 Feb;83(2):822-31.
[Content Brief]